25 analysts have expressed a variety of opinions on Edwards Lifesciences EW over the past quarter, offering a diverse set of opinions from bullish to bearish.
The following table summarizes their recent ratings, shedding light on the changing sentiments within the past 30 days and comparing them to the preceding months.
| Bullish | Somewhat Bullish | Indifferent | Somewhat Bearish | Bearish | |
|---|---|---|---|---|---|
| Total Ratings | 5 | 7 | 13 | 0 | 0 |
| Last 30D | 1 | 0 | 1 | 0 | 0 |
| 1M Ago | 0 | 3 | 3 | 0 | 0 |
| 2M Ago | 0 | 0 | 0 | 0 | 0 |
| 3M Ago | 4 | 4 | 9 | 0 | 0 |
Analysts' evaluations of 12-month price targets offer additional insights, showcasing an average target of $81.0, with a high estimate of $110.00 and a low estimate of $70.00. Experiencing a 14.84% decline, the current average is now lower than the previous average price target of $95.12.
Investigating Analyst Ratings: An Elaborate Study
A comprehensive examination of how financial experts perceive Edwards Lifesciences is derived from recent analyst actions. The following is a detailed summary of key analysts, their recent evaluations, and adjustments to ratings and price targets.
| Analyst | Analyst Firm | Action Taken | Rating | Current Price Target | Prior Price Target |
|---|---|---|---|---|---|
| Vijay Kumar | Evercore ISI Group | Lowers | In-Line | $70.00 | $76.00 |
| Joanne Wuensch | Citigroup | Lowers | Buy | $77.00 | $83.00 |
| Matthew Taylor | Jefferies | Lowers | Hold | $70.00 | $85.00 |
| Richard Newitter | Truist Securities | Lowers | Hold | $71.00 | $82.00 |
| Suraj Kalia | Oppenheimer | Maintains | Outperform | $90.00 | $90.00 |
| Danielle Antalffy | UBS | Lowers | Neutral | $75.00 | $90.00 |
| Matt Miksic | Barclays | Lowers | Overweight | $80.00 | $90.00 |
| Larry Biegelsen | Wells Fargo | Lowers | Overweight | $80.00 | $90.00 |
| Matt Miksic | Barclays | Lowers | Overweight | $90.00 | $101.00 |
| David Roman | Goldman Sachs | Lowers | Buy | $91.00 | $107.00 |
| Joshua Jennings | TD Cowen | Lowers | Hold | $70.00 | $100.00 |
| Larry Biegelsen | Wells Fargo | Lowers | Overweight | $90.00 | $99.00 |
| Vijay Kumar | Evercore ISI Group | Lowers | In-Line | $76.00 | $91.00 |
| Pito Chickering | Deutsche Bank | Lowers | Buy | $85.00 | $103.00 |
| Shagun Singh | RBC Capital | Lowers | Outperform | $85.00 | $101.00 |
| Richard Newitter | Truist Securities | Lowers | Hold | $82.00 | $110.00 |
| Rick Wise | Stifel | Lowers | Hold | $70.00 | $85.00 |
| Suraj Kalia | Oppenheimer | Lowers | Outperform | $90.00 | $100.00 |
| William Plovanic | Canaccord Genuity | Lowers | Hold | $77.00 | $85.00 |
| Adam Maeder | Piper Sandler | Lowers | Neutral | $73.00 | $88.00 |
| Travis Steed | B of A Securities | Lowers | Neutral | $75.00 | $105.00 |
| Robbie Marcus | JP Morgan | Lowers | Neutral | $72.00 | $105.00 |
| David Rescott | Baird | Lowers | Neutral | $70.00 | $102.00 |
| Richard Newitter | Truist Securities | Raises | Buy | $110.00 | $105.00 |
| Joanne Wuensch | Citigroup | Raises | Buy | $106.00 | $105.00 |
Key Insights:
- Action Taken: Analysts adapt their recommendations to changing market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their response to recent developments related to Edwards Lifesciences. This information provides a snapshot of how analysts perceive the current state of the company.
- Rating: Analyzing trends, analysts offer qualitative evaluations, ranging from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Edwards Lifesciences compared to the broader market.
- Price Targets: Analysts predict movements in price targets, offering estimates for Edwards Lifesciences's future value. Examining the current and prior targets offers insights into analysts' evolving expectations.
Assessing these analyst evaluations alongside crucial financial indicators can provide a comprehensive overview of Edwards Lifesciences's market position. Stay informed and make well-judged decisions with the assistance of our Ratings Table.
Stay up to date on Edwards Lifesciences analyst ratings.
Discovering Edwards Lifesciences: A Closer Look
Spun off from Baxter International in 2000, Edwards Lifesciences designs, manufactures, and markets a range of medical devices and equipment for advanced stages of structural heart disease. It has established itself as a leader across key products, including surgical tissue heart valves, transcatheter valve technologies, surgical clips, and catheters. The firm derives about 55% of its total sales from outside the US.
Financial Milestones: Edwards Lifesciences's Journey
Market Capitalization Analysis: Falling below industry benchmarks, the company's market capitalization reflects a reduced size compared to peers. This positioning may be influenced by factors such as growth expectations or operational capacity.
Revenue Growth: Over the 3 months period, Edwards Lifesciences showcased positive performance, achieving a revenue growth rate of 6.98% as of 30 June, 2024. This reflects a substantial increase in the company's top-line earnings. As compared to its peers, the revenue growth lags behind its industry peers. The company achieved a growth rate lower than the average among peers in Health Care sector.
Net Margin: The company's net margin is a standout performer, exceeding industry averages. With an impressive net margin of 26.43%, the company showcases strong profitability and effective cost control.
Return on Equity (ROE): Edwards Lifesciences's ROE stands out, surpassing industry averages. With an impressive ROE of 5.03%, the company demonstrates effective use of equity capital and strong financial performance.
Return on Assets (ROA): Edwards Lifesciences's ROA stands out, surpassing industry averages. With an impressive ROA of 3.69%, the company demonstrates effective utilization of assets and strong financial performance.
Debt Management: Edwards Lifesciences's debt-to-equity ratio is below the industry average at 0.09, reflecting a lower dependency on debt financing and a more conservative financial approach.
Understanding the Relevance of Analyst Ratings
Within the domain of banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their work involves attending company conference calls and meetings, researching company financial statements, and communicating with insiders to publish "analyst ratings" for stocks. Analysts typically assess and rate each stock once per quarter.
Some analysts publish their predictions for metrics such as growth estimates, earnings, and revenue to provide additional guidance with their ratings. When using analyst ratings, it is important to keep in mind that stock and sector analysts are also human and are only offering their opinions to investors.
If you want to keep track of which analysts are outperforming others, you can view updated analyst ratings along withanalyst success scores in Benzinga Pro.
Which Stocks Are Analysts Recommending Now?
Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. Click here to stay ahead of the market.
This article was generated by Benzinga's automated content engine and reviewed by an editor.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
date | ticker | name | Price Target | Upside/Downside | Recommendation | Firm |
|---|
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
